Table of Contents: 2022 MAY–JUNE No. 446
RxNorm June 2022 Monthly Release. NLM Tech Bull. 2022 May-Jun;(446):b8.
The RxNorm June 2022 monthly release became available on Monday, June 6, 2022, and includes several COVID-19 medication updates.
Sotrovimab Status Change
The U.S. Food and Drug Administration (FDA) determined that sotrovimab is no longer authorized to treat COVID-19 in any U.S. region earlier this year. The RxNorm data reflects this by the lack of both the Attribute Name (ATN) "RXN_HUMAN_DRUG" and a corresponding Attribute Value (ATV) for RxNorm Concept Unique Identifier (RXCUI) 2550903 with string "8 ML sotrovimab 62.5 MG/ML Injection." The RxNorm terminology (SAB=RXNORM) National Drug Code is also absent, and the "(EUA)" in the Prescribable Name (PSN) has been deleted.
Get more information about sotrovimab from the FDA:
New Spikevax COVID-19 Vaccine Concept Added
The Moderna COVID-19 vaccine will be marketed as Spikevax. To reflect this change, a Semantic Branded Drug (SBD) concept for Spikevax will be in the RxNorm June monthly release.
Here is the new Spikevax COVID-19 vaccine concept in RxNorm:
| RXCUI | Term Type (TTY) | STRING |
| 2601552 | SBD | SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 0.2 MG/ML Injectable Suspension [Spikevax] |
Get more information about Spikevax from the FDA:
